Evaluation Increasing Access to Improve Outcomes: Exploring the Role of Biosimilars in the Management of Inflammatory Bowel Disease Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the utility of biosimilars for IBD and their potential impact on reducing costs and improving access to treatment 5 4 3 2 1 Assess common misconceptions regarding biosimilar testing and discuss the approval process for determining the safety and efficacy of biosimilars in clinical practice 5 4 3 2 1 Evaluate the most recent data regarding the safety and efficacy of current and emerging biosimilars for the treatment of IBD 5 4 3 2 1 Outline strategies to incorporate the use of biosimilars in clinical practice, including clinician and patient education on their safety and efficacy as well as appropriate reasons for switching medications 5 4 3 2 1 Please rate the faculty on the following: Christina Ha, MD, FACG, AGAF: Knowledge, expertise, and teaching ability 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with IBD do you see during a typical week? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No According to a recent report, the availability and use of biosimilar medicines has the potential to reduce drug costs by ________ over the next 5 years. $100 Million $500 Million $100 Billion $500 Billion In which of the following clinical scenarios may a biosimilar be considered? If the patient experienced clinically significant antibodies to the reference product If the patient exhibited primary non-response to the reference product Following a drug holiday after previous history of response to the reference product If the patient experienced moderate-to-severe side effects to the reference product Biosimilar __________ is determined by regulatory/legal authorities based on totality of evidence presented. Bioequivalence Extrapolation Interchangeability Pharmacovigilance Which of the following was the first FDA-approved interchangeable biosimilar product for its reference product: Adalimumab-adbm Adalimumab-aacf Infliximab-abda Infliximab-dyyb Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often: (select all that apply) Remain apprised of current and emerging clinical data regarding the safety and efficacy of biosimilars Recommend a biosimilar as induction therapy when appropriate Switch a patient to a biosimilar when clinically appropriate Educate patients on the differences between generics and biosimilars Discuss the FDA approval process for biosimilars with patients who are considering biosimilar treatment Other (please specify): How confident are you in your ability to optimally integrate biosimilars into clinical practice, when appropriate, for the treatment of IBD? Very confident Confident Somewhat confident Not very confident Not at all confident Previous
